CO2020010047A2 - Métodos de terapia de testosterona - Google Patents

Métodos de terapia de testosterona

Info

Publication number
CO2020010047A2
CO2020010047A2 CONC2020/0010047A CO2020010047A CO2020010047A2 CO 2020010047 A2 CO2020010047 A2 CO 2020010047A2 CO 2020010047 A CO2020010047 A CO 2020010047A CO 2020010047 A2 CO2020010047 A2 CO 2020010047A2
Authority
CO
Colombia
Prior art keywords
trt
methods
side effects
therapy methods
testosterone
Prior art date
Application number
CONC2020/0010047A
Other languages
English (en)
Inventor
Nathan Bryson
Gerwin Westfield
Margaux Zwierko
Ranjith Ramasamy
Original Assignee
Acerus Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acerus Biopharma Inc filed Critical Acerus Biopharma Inc
Publication of CO2020010047A2 publication Critical patent/CO2020010047A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a métodos y sistemas para prevenir o reducir los efectos secundarios de la terapia de reemplazo de testosterona (TRT) administrando una formulación de testosterona múltiples veces por día. Los métodos de la presente invención permiten a los hombres quiénes no pueden tolerar regímenes de TRT previos, por ejemplo, debido a que desean intentar concebir o están en riesgo de desarrollar efectos secundarios cardiovasculares, recibir tratamiento de TRT.
CONC2020/0010047A 2018-02-02 2020-08-14 Métodos de terapia de testosterona CO2020010047A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862625653P 2018-02-02 2018-02-02
US201862756976P 2018-11-07 2018-11-07
PCT/US2019/016373 WO2019152854A1 (en) 2018-02-02 2019-02-01 Methods of testosterone therapy

Publications (1)

Publication Number Publication Date
CO2020010047A2 true CO2020010047A2 (es) 2020-11-10

Family

ID=67476262

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0010047A CO2020010047A2 (es) 2018-02-02 2020-08-14 Métodos de terapia de testosterona

Country Status (15)

Country Link
US (2) US20190240237A1 (es)
EP (1) EP3710012A4 (es)
JP (1) JP2021512868A (es)
KR (1) KR20200118039A (es)
CN (1) CN112020361A (es)
AU (1) AU2019215163A1 (es)
BR (1) BR112020015650A2 (es)
CA (1) CA3090262A1 (es)
CO (1) CO2020010047A2 (es)
IL (1) IL276421A (es)
MX (1) MX2020008147A (es)
PH (1) PH12020551164A1 (es)
SG (1) SG11202007303YA (es)
WO (1) WO2019152854A1 (es)
ZA (1) ZA202004657B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002017927A1 (en) * 2000-08-30 2002-03-07 Unimed Pharmaceuticals, Inc. Method for treating erectile dysfunction and increasing libido in men
DE102005015128B4 (de) * 2005-03-31 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Wafer enthaltend Steroidhormone
US8962818B2 (en) * 2008-03-06 2015-02-24 Vgx Pharmaceuticals, Inc. Compositions comprising GHRH and GnRH and methods of using the same
GB2482868A (en) * 2010-08-16 2012-02-22 Franciscus Wilhelmus Henricus Maria Merkus A testosterone liquid spray formulation for oromucosal administration
WO2012156820A1 (en) * 2011-05-15 2012-11-22 Trimel Pharmaceuticals Corp. Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism
CN105362667A (zh) * 2015-12-03 2016-03-02 钟柱林 一种防治生精障碍的中药提取物及其应用

Also Published As

Publication number Publication date
AU2019215163A1 (en) 2020-08-20
MX2020008147A (es) 2020-10-28
US20220152049A1 (en) 2022-05-19
IL276421A (en) 2020-09-30
SG11202007303YA (en) 2020-08-28
PH12020551164A1 (en) 2021-05-31
EP3710012A1 (en) 2020-09-23
CA3090262A1 (en) 2019-08-08
BR112020015650A2 (pt) 2020-12-08
ZA202004657B (en) 2023-08-30
KR20200118039A (ko) 2020-10-14
JP2021512868A (ja) 2021-05-20
CN112020361A (zh) 2020-12-01
WO2019152854A1 (en) 2019-08-08
US20190240237A1 (en) 2019-08-08
EP3710012A4 (en) 2021-07-28

Similar Documents

Publication Publication Date Title
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CO2020006248A2 (es) Moduladores de la vía de estrés integrada
CL2018000198A1 (es) Composiciones de arni de transtiretina (ttr) y métodos para su uso para el tratamiento o prevencion de enfermedades asociadas con ttr
CL2017002904A1 (es) Métodos y kits para tratar la depresión
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
ECSP20027553A (es) Moduladores de la vía de estrés integrada
BR112018006259A2 (pt) "adjunto compressível com estruturas de suporte intermediárias"
BR112018013995A2 (pt) terapia de combinação de vírus oncolítico e inibidor de ponto de verificação
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
ECSP17059323A (es) Formulacion de combinacion de tesofensina y betabloqueante
NI202100018A (es) Moduladores de la expresión de pnpla3
BR112019003049A2 (pt) sistema de fixação óssea
CO2023004346A2 (es) Formulaciones de un modulador de somatostatina
CR20190471A (es) Moduladores de la expresión de pcsk9
CO2022000270A2 (es) Inhibidores de enzimas
CO2017002356A2 (es) Métodos para tratar la depresión usando moduladores de nmda
CL2021001246A1 (es) Moduladores de expresión irf5.
CR20170061A (es) Métodos y composiciones para el tratamiento de trastornos relacionados con vih
BR112016016901A2 (pt) agentes para o uso no tratamento de inflamação retinal
CO2020010047A2 (es) Métodos de terapia de testosterona
UY38472A (es) Moduladores de la expresión de foxp3
MX2020003554A (es) Moduladores de la expresion de enac.
CL2018000573A1 (es) Composiciones para activación de nrf2 mejoraday sus métodos de uso
CO2022009433A2 (es) Uso de isatuximab para el tratamiento del mieloma múltiple recidivante y/o refractario